期刊
NATURE COMMUNICATIONS
卷 5, 期 -, 页码 -出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/ncomms6068
关键词
-
资金
- Bristol-Myers Squibb, USA
- European Union [HEALTH-F2-2009-223004]
- Netherlands Consortium for Healthy Ageing (NGI) [05060810]
- Pfizer, USA
- National Institutes for Health Research (NIHR) as part of the portfolio of translational research of the NIHR Biomedical Research Unit at Barts
- NIHR Biomedical Research Centre at Imperial College
- International Centre for Circulatory Health Charity
- Medical Research Council [G952010]
- Pfizer, Diabetes UK
- Department of Health
- National Institutes of Health from the National Heart, Lung, and Blood Institute [U19 HL069757]
- National Center for Advancing Translational Sciences [UL1TR000124, 2 UL1 TR000445]
- Pfizer
- NIH [N01-AG-1-2100]
- NIA Intramural Research Program, Hjartavernd (the Icelandic Heart Association)
- Althingi (the Icelandic Parliament)
- National Heart, Lung, and Blood Institute contracts [HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, HHSN268201100012C, R01HL087641, R01HL59367, R01HL086694]
- National Human Genome Research Institute contract [U01HG004402]
- National Institutes of Health contract [HHSN268200625226C]
- National Institutes of Health and NIH Roadmap for Medical Research [UL1RR025005]
- National Center for Research Resources [UL1 RR024975]
- National Human Genome Research Institute [U01-HG04603]
- National Insitute of General Medical Sciences [RC2-GM092318]
- NHLBI [HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, HL080295, N01HC85086, HL087652, HL105756, HL103612, HL085251, HL073410, HL068986]
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institute on Aging (NIA) [AG023629]
- National Center for Advancing Translational Sciences
- CTSI grant [UL1TR000124]
- National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant [DK063491]
- National Heart Lung and Blood Institute of the National Institutes of Health
- Boston University School of Medicine [N01-HC-25195]
- Affymetrix, Inc. [N02-HL-6-4278]
- Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine
- Boston Medical Center [R01HL103612]
- Wellcome Trust United Kingdom Type 2 Diabetes Case Control Collection (GoDARTS)
- Scottish Health Informatics Programme
- Wellcome Trust Case Control Consortium
- Diabetes UK [07/0003525]
- Wellcome Trust [084727/Z/08/Z, 085475/Z/08/Z, 085475/B/08/Z]
- EU IMI-SUMMIT programme
- NIA [N01AG62101, N01AG62103, N01AG62106, 1R01AG032098-01A1]
- National Institutes of Health [HHSN268200782096C]
- Intramural Research Program of the NIH, National Institute on Aging
- National Heart, Lung, and Blood Institute (NHLBI)
- MESA investigators
- Clinical Translational Science Institute grant [UL1RR033176]
- AstraZeneca
- Erasmus Medical Center
- Erasmus University Rotterdam
- Netherlands Organization for Health Research and Development (ZonMw)
- Research Institute for Diseases in the Elderly
- Ministry of Education, Culture and Science
- Ministry of Health Welfare and Sports
- European Commission
- Municipality of Rotterdam
- Netherlands Genomics Initiative (NGI) Netherlands Organization for Scietific Research (NOW) [050-060-810]
- [N01 HC-95159]
- [N01-HC-95169]
- [RR024156]
- MRC [G0400126, G9521010] Funding Source: UKRI
- British Heart Foundation [PG/13/66/30442] Funding Source: researchfish
- Medical Research Council [MR/K006584/1, G0400126, G9521010] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0513-10059, NF-SI-0512-10113] Funding Source: researchfish
Statins effectively lower LDL cholesterol levels in large studies and the observed interindividual response variability may be partially explained by genetic variation. Here we perform a pharmacogenetic meta-analysis of genome-wide association studies (GWAS) in studies addressing the LDL cholesterol response to statins, including up to 18,596 statin-treated subjects. We validate the most promising signals in a further 22,318 statin recipients and identify two loci, SORT1/CELSR2/PSRC1 and SLCO1B1, not previously identified in GWAS. Moreover, we confirm the previously described associations with APOE and LPA. Our findings advance the understanding of the pharmacogenetic architecture of statin response.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据